

Robert Yarchoan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3859470/publications.pdf>

Version: 2024-02-01

72
papers

7,198
citations

76322

40
h-index

88628

70
g-index

74
all docs

74
docs citations

74
times ranked

5731
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. Journal of Clinical Oncology, 2022, 40, 294-306.	1.6	17
2	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Science Translational Medicine, 2022, 14, eab13836.	12.4	50
3	Safety, Activity, and Long-term Outcomes of Pomalidomide in the Treatment of Kaposi Sarcoma among Individuals with or without HIV Infection. Clinical Cancer Research, 2022, 28, 840-850.	7.0	20
4	Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide. Frontiers in Medicine, 2022, 9, .	2.6	4
5	CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules. Journal of Translational Medicine, 2022, 20, 217.	4.4	9
6	Immunotherapy for KSHV-associated diseases. Current Opinion in Virology, 2022, 55, 101249.	5.4	4
7	A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications, 2021, 12, 668.	12.8	126
8	Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma. , 2021, 9, e002097.		28
9	Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases. Blood Advances, 2021, 5, 1660-1670.	5.2	35
10	Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300. MBio, 2021, 12, e0209421.	4.1	13
11	Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2. PLoS Pathogens, 2021, 17, e1009091.	4.7	16
12	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nature Genetics, 2020, 52, 800-810.	21.4	40
13	GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection. MBio, 2020, 11, .	4.1	52
14	Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer. Current HIV/AIDS Reports, 2020, 17, 547-556.	3.1	21
15	Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood, 2020, 135, 2316-2319.	1.4	33
16	Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate. Blood, 2020, 136, 2229-2232.	1.4	26
17	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Thymidine Kinase (ORF21) by X-Box Binding Protein 1. Journal of Virology, 2020, 94, .	3.4	6
18	A phase I trial of pomalidomide in combination with liposomal doxorubicin in patients with Kaposi sarcoma with or without other KSHV-associated diseases.. Journal of Clinical Oncology, 2020, 38, 11552-11552.	1.6	3

#	ARTICLE	IF	CITATIONS
19	No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. <i>Science Advances</i> , 2019, 5, eaav2045.	10.3	60
20	Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. <i>Oncolimmunology</i> , 2019, 8, e1546544.	4.6	23
21	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. <i>JAMA Oncology</i> , 2019, 5, 1332.	7.1	153
22	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. <i>Clinical Cancer Research</i> , 2019, 25, 4238-4247.	7.0	17
23	Viral, immunologic, and clinical features of primary effusion lymphoma. <i>Blood</i> , 2019, 133, 1753-1761.	1.4	87
24	HIV-Associated Cancers and Related Diseases. <i>New England Journal of Medicine</i> , 2018, 378, 1029-1041.	27.0	327
25	Metagenomic Discovery of 83 New Human Papillomavirus Types in Patients with Immunodeficiency. <i>MSphere</i> , 2018, 3, .	2.9	75
26	HIV-Associated Cancers and Related Diseases. <i>New England Journal of Medicine</i> , 2018, 378, 2144-2145.	27.0	33
27	Identification of functional hypoxia inducible factor response elements in the human lysyl oxidase gene promoter. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 480-485.	2.1	33
28	Kaposi sarcoma herpesvirus-associated cancers and related diseases. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 47-56.	3.8	120
29	HIV-associated Kaposi sarcoma and related diseases. <i>Aids</i> , 2017, 31, 1903-1916.	2.2	97
30	A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. <i>ELife</i> , 2017, 6, .	6.0	44
31	RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. <i>PLoS Pathogens</i> , 2017, 13, e1006143.	4.7	28
32	T-cell responses to KSHV infection: a systematic approach. <i>Oncotarget</i> , 2017, 8, 109402-109416.	1.8	29
33	Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma. <i>PLoS Pathogens</i> , 2017, 13, e1006628.	4.7	30
34	Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. <i>Oncotarget</i> , 2017, 8, 50342-50358.	1.8	28
35	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 4125-4131.	1.6	91
36	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). <i>Clinical Infectious Diseases</i> , 2016, 62, 730-738.	5.8	135

#	ARTICLE	IF	CITATIONS
37	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. <i>Journal of Virology</i> , 2016, 90, 368-378.	3.4	26
38	Next-Generation Sequencing Analysis Reveals Differential Expression Profiles of MiRNA-mRNA Target Pairs in KSHV-Infected Cells. <i>PLoS ONE</i> , 2015, 10, e0126439.	2.5	19
39	Kaposi Sarcoma—Associated Herpesvirus-Associated Malignancies: Epidemiology, Pathogenesis, and Advances in Treatment. <i>Seminars in Oncology</i> , 2015, 42, 223-246.	2.2	122
40	Inflammatory Cytokines, Hyperferritinemia and IgE Are Prognostic in Patients with KSHV-Associated Lymphomas Treated with Curative Intent Therapy. <i>Blood</i> , 2014, 124, 3001-3001.	1.4	3
41	Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castlemann disease. <i>Blood</i> , 2013, 122, 4189-4198.	1.4	141
42	Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Induction by Hypoxia and Hypoxia-Inducible Factors. <i>Journal of Virology</i> , 2012, 86, 1097-1108.	3.4	34
43	Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 1476-1483.	1.6	103
44	Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castlemann Disease (KSHV—MCD) and the KSHV Inflammatory Cytokine Syndrome. <i>Frontiers in Microbiology</i> , 2012, 3, 73.	3.5	150
45	High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castlemann disease: a pilot study of virus-activated cytotoxic therapy. <i>Blood</i> , 2011, 117, 6977-6986.	1.4	149
46	Kaposi's sarcoma—associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. <i>Journal of Pathology</i> , 2011, 225, 378-389.	4.5	59
47	Cancer Burden in the HIV-Infected Population in the United States. <i>Journal of the National Cancer Institute</i> , 2011, 103, 753-762.	6.3	698
48	Characterization of the Activation of Protein Tyrosine Phosphatase, Receptor-Type, Z Polypeptide 1 (PTPRZ1) by Hypoxia Inducible Factor-2 Alpha. <i>PLoS ONE</i> , 2010, 5, e9641.	2.5	27
49	An Interleukin-6—Related Systemic Inflammatory Syndrome in Patients Co-Infected with Kaposi Sarcoma—Associated Herpesvirus and HIV but without Multicentric Castlemann Disease. <i>Clinical Infectious Diseases</i> , 2010, 51, 350-358.	5.8	266
50	Hypoxia Enhances the Phosphorylation and Cytotoxicity of Ganciclovir and Zidovudine in Kaposi's Sarcoma-Associated Herpesvirus—Infected Cells. <i>Cancer Research</i> , 2007, 67, 7003-7010.	0.9	44
51	Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. <i>Blood</i> , 2007, 110, 4165-4171.	1.4	51
52	Genetic Organization and Hypoxic Activation of the Kaposi's Sarcoma-Associated Herpesvirus ORF34-37 Gene Cluster. <i>Journal of Virology</i> , 2006, 80, 7037-7051.	3.4	59
53	Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1 α and Hypoxia-Inducible Factor-2 β in HEK293T Cells. <i>Cancer Research</i> , 2005, 65, 3299-3306.	0.9	282
54	Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Contains Hypoxia Response Elements: Relevance to Lytic Induction by Hypoxia. <i>Journal of Virology</i> , 2003, 77, 6761-6768.	3.4	107

#	ARTICLE	IF	CITATIONS
55	Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood, 2001, 97, 3244-3250.	1.4	220
56	Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood, 2001, 97, 2173-2176.	1.4	114
57	Transcription Program of Human Herpesvirus 8 (Kaposi's Sarcoma-Associated Herpesvirus). Journal of Virology, 2001, 75, 4843-4853.	3.4	198
58	Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. Journal of Clinical Oncology, 2000, 18, 2593-2602.	1.6	288
59	Involvement of Interleukin-10 (IL-10) and Viral IL-6 in the Spontaneous Growth of Kaposi's Sarcoma Herpesvirus-Associated Infected Primary Effusion Lymphoma Cells. Blood, 1999, 94, 2871-2879.	1.4	228
60	Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood, 1999, 94, 2871-9.	1.4	114
61	Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.. Journal of Clinical Oncology, 1998, 16, 1112-1121.	1.6	162
62	Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clinical Pharmacology and Therapeutics, 1991, 50, 278-285.	4.7	63
63	Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood, 1991, 78, 859-84.	1.4	24
64	Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 1990, 47, 647-654.	4.7	148
65	Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection [see comments]. Blood, 1990, 76, 463-472.	1.4	101
66	Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet, The, 1990, 336, 526-529.	13.7	233
67	Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection [see comments]. Blood, 1990, 76, 463-472.	1.4	0
68	Strategies for the combination therapy of HIV infection. Journal of Acquired Immune Deficiency Syndromes, 1990, 3 Suppl 2, S99-103.	1.0	1
69	In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science, 1989, 245, 412-415.	12.6	424
70	Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddc). Muscle and Nerve, 1989, 12, 856-860.	2.2	110
71	Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clinical Pharmacology and Therapeutics, 1989, 46, 494-499.	4.7	120
72	Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clinical Pharmacology and Therapeutics, 1987, 41, 407-412.	4.7	396